InvestorsHub Logo
Followers 14
Posts 603
Boards Moderated 0
Alias Born 12/27/2017

Re: olden_grumpini post# 385585

Thursday, 12/02/2021 1:11:20 PM

Thursday, December 02, 2021 1:11:20 PM

Post# of 402726
100% agreement.

Running numbers here, I don't see this ever turning out positive for long-time shareholders. I've been holding for 5yrs now and over $1 basis... and seriously considering ditching now before holdings go to zero if Leo ever R/S's us. He's maintained that he wouldn't, but desperate times and all.

I have zero confidence in AlfaSigma doing anything to move this in any sort of forward direction based on the lack of progress and the size of the 'deal'. I believe it to be inconsequential.

The 'executive salary' nightmare here is massively problematic as well, with the company not making a dime and further diluting SH to pay Leo/Jane $1M+/yr. That's bat-shit insanity.

OM and IBD will require more cash to develop than is on-hand or raiseable in the foreseeable future.

I feel like it's done for us here.

Leo wins with his scam bioTech and shareholders burn to the ground.

A lawsuit might be time and money better spent at this juncture?


Thoughtful post. Your last sentence sums up the mistake that so many retail investors, including myself, make: they think “hope” is a key part of an investment strategy. Smart money is dispassionate.

Smart money, in addition to researching the competitive landscape, understands dilution/predatory financing, reads source SEC filings, and comprehends research and how data extrapolates to the real world (e.g., the paper published in viruses strongly suggested [screamed?] that brilacidin would not work in the clinical trial as designed by IPIX).

Can a case can be made for buying IPIX at these prices? One argument would be that IPIX must raise the closing price to be >$0.10/share in order to access the Aspire financing. IPIX is dead in the water without the Aspire money. If you bought at $0.067 and sold at $0.10 you would make almost 50%. That’s pretty good if it happens. What are the counter arguments? Reverse stock split (1:2 means your basis doubled while the Aspire deal can still take place at $0.10)? Company sold for $0.05/share? CEO becomes incapacitated and sp craters? Company goes into suspended animation until patents/licenses run out?

BTW: The Aspire deal ends in late July. The money comes from Aspire in a dribble, not a gusher, so IPIX will need a significant number of trading days to achieve their financing needs. And there will be dilution, oh yeah. For example, if IPIX gets the sp above $0.10/share and starts putting the shares to Aspire on January 10th, and wants to access the full $25.4 million between then and end of July, and the share price averages $0.15/share during that period, there will be average daily dilution of >1.2 million shares.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News